Legal & General Group Plc Acquires Shares of 89,623 Immunome, Inc. $IMNM

Legal & General Group Plc purchased a new position in Immunome, Inc. (NASDAQ:IMNM) in the 2nd quarter, HoldingsChannel reports. The firm purchased 89,623 shares of the company’s stock, valued at approximately $1,899,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Creative Planning increased its position in shares of Immunome by 4.0% during the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock valued at $219,000 after purchasing an additional 710 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Immunome by 14.4% during the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after purchasing an additional 935 shares during the last quarter. Allworth Financial LP bought a new stake in Immunome during the 2nd quarter valued at about $25,000. California State Teachers Retirement System boosted its holdings in shares of Immunome by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after purchasing an additional 1,167 shares during the period. Finally, Assetmark Inc. grew its position in shares of Immunome by 46.6% during the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after buying an additional 1,442 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Insider Transactions at Immunome

In other news, Director Isaac Barchas sold 11,048 shares of Immunome stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $27.25, for a total value of $301,058.00. Following the sale, the director owned 92,211 shares of the company’s stock, valued at $2,512,749.75. The trade was a 10.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of Immunome stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total value of $2,273,555.44. Following the completion of the sale, the insider owned 50,366 shares in the company, valued at approximately $1,263,682.94. This trade represents a 64.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 682,310 shares of company stock worth $15,675,566 over the last 90 days. 7.21% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

IMNM has been the topic of a number of analyst reports. Barclays began coverage on Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target on the stock. Wedbush increased their price objective on Immunome from $31.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Wall Street Zen cut shares of Immunome from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.64.

Immunome Price Performance

Shares of Immunome stock opened at $26.76 on Monday. Immunome, Inc. has a 12 month low of $8.66 and a 12 month high of $30.06. The business has a 50-day moving average of $24.96 and a 200 day moving average of $22.58. The stock has a market capitalization of $3.04 billion, a price-to-earnings ratio of -10.58 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). Equities research analysts anticipate that Immunome, Inc. will post -2.38 earnings per share for the current year.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.